NYSE · LLY
Eli Lilly and Company
$1,437.74+$64.04 (+4.66%)
Eli Lilly and Company’s quoted price is above the reported 52-week high. The range and quote may have different update times.
Loading market information…
NASDAQ · NVIV · USD
Stock price, earnings
Quote as of Feb 12, 2024, 09:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
InVivo Therapeutics Holdings Corporation’s quoted price sits in the lower half of its reported 52-week range, 86.64% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow InVivo Therapeutics Holdings Corporation’s reporting calendar.
THE COMPANY BEHIND THE TICKER
InVivo Therapeutics Holdings Corp. is a biotechnology and biomaterials firm, actively involved in research and clinical development. The company specializes in creating and bringing to market innovative biopolymer scaffolding devices designed to address spinal cord injuries (SCI). Its primary investigational product is the Neuro-Spinal Scaffold implant, a bioresorbable polymer scaffold. This device is engineered to be implanted directly at the site of injury within the spinal cord, aiming to treat acute SCI. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:41 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
THE ANALYST VIEW
3 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1,437.74+$64.04 (+4.66%)
Eli Lilly and Company’s quoted price is above the reported 52-week high. The range and quote may have different update times.
$0.41$0.00 (0.0%)
CohBar, Inc.’s quoted price sits in the lower half of its reported 52-week range, 59.41% below the high.
$0.34+$0.00 (+0.74%)
Timber Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 89.89% below the high.
$0.30+$0.30 (+100.0%)
Altamira Therapeutics Ltd.’s quoted price sits in the lower half of its reported 52-week range, 27.85% below the high.
$0.04-$0.02 (-27.27%)
Impel Pharmaceuticals Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.05% below the high.
$0.51-$0.16 (-23.29%)
Lucy Scientific Discovery Inc.’s quoted price sits in the lower half of its reported 52-week range, 95.99% below the high.
$0.03$0.00 (0.0%)
Accelerate Diagnostics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.37% below the high.
$0.07-$0.01 (-6.68%)
Bellicum Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 94.29% below the high.
